SOURCE: Crucell N.V.

May 30, 2007 08:07 ET

Crucell announces live webcast of Annual General Meeting of Shareholders

LEIDEN, NETHERLANDS--(Marketwire - May 30, 2007) -



Leiden, The Netherlands, May 30 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced that there will be a live video webcast of the Annual General Meeting of Shareholders (AGM), commencing June 1 at 14:00 hrs CET in Leiden. The webcast will be available via Crucell's corporate website, www.crucell.com, where you can also find general information regarding the AGM.


About Crucell

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminium-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit www.crucell.com.


Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on July 6, 2006, and the section entitled "Risk Factors". The Company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS).

For further information please contact:


Crucell N.V.                      For Crucell in the US:
Leonard Kruimer                   Redington, Inc.
Chief Financial Officer           Thomas Redington
Tel. +31-(0)71- 519 9100          Tel. +1 212-926-1733
Leonard.Kruimer@crucell.com       tredington@redingtoninc.com

Barbara Mulder
Director Corporate Communications
Tel: 31-(0) 71 519 7346
barbara.mulder@crucell.com




Copyright © Hugin ASA 2007. All rights reserved.

Contact Information